(TBI) TrueBlue - Ratings and Ratios
Staffing, Recruitment, Outsourcing, Workforce, Contingent
TBI EPS (Earnings per Share)
TBI Revenue
Description: TBI TrueBlue October 29, 2025
TrueBlue, Inc. (NYSE:TBI) delivers workforce-solution services across the United States, Canada, the United Kingdom, Australia, and Puerto Rico through three operating segments: PeopleReady, PeopleManagement, and PeopleScout.
PeopleReady, the largest segment, supplies general, industrial, and skilled-trade contingent labor to construction, transportation, manufacturing, retail, hospitality, and energy firms, and historically generates roughly 70 % of the company’s revenue.
PeopleManagement focuses on on-site industrial staffing and commercial-driver services, operating under the Staff Management, SIMOS Insourcing Solutions, and Centerline Drivers brands; it targets manufacturing, warehousing, distribution, and transportation customers that require managed labor pools.
PeopleScout offers recruitment-process outsourcing, talent-advisory, and managed-service-provider solutions, including the Affinix technology platform, employer-branding services, and compliance-monitoring programs for contingent-labor programs.
Key financial and market context (FY 2023): revenue of approximately $1.1 billion, adjusted EBITDA margin near 7 %, and a 4 % YoY increase in PeopleReady billings, driven by a sustained construction hiring boom and persistent labor-shortage pressures that favor contingent staffing models.
Sector-level drivers include a low-unemployment environment, rising wage inflation, and a projected 10 % CAGR growth in the U.S. recruitment-process-outsourcing market, all of which create tailwinds for TrueBlue’s diversified service lines.
For a deeper, data-driven view of TrueBlue’s valuation metrics, you might explore the analyst dashboards on ValueRay.
TBI Stock Overview
| Market Cap in USD | 145m |
| Sub-Industry | Human Resource & Employment Services |
| IPO / Inception | 1996-06-13 |
TBI Stock Ratings
| Growth Rating | -78.0% |
| Fundamental | 15.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -46.7% |
| Analyst Rating | 4.0 of 5 |
TBI Dividends
Currently no dividends paidTBI Growth Ratios
| Growth Correlation 3m | -55.3% |
| Growth Correlation 12m | -50.8% |
| Growth Correlation 5y | -91.4% |
| CAGR 5y | -38.67% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.47 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.82 |
| Sharpe Ratio 12m | -0.59 |
| Alpha | -58.12 |
| Beta | 1.541 |
| Volatility | 71.23% |
| Current Volume | 195.5k |
| Average Volume 20d | 261.8k |
| Stop Loss | 4.6 (-6.3%) |
| Signal | 1.30 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-33.8m TTM) > 0 and > 6% of Revenue (6% = 92.1m TTM) |
| FCFTA -0.08 (>2.0%) and ΔFCFTA -3.85pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.04% (prev 8.08%; Δ 0.96pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.05 (>3.0%) and CFO -34.9m <= Net Income -33.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.94 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.9m) change vs 12m ago -1.62% (target <= -2.0% for YES) |
| Gross Margin 24.47% (prev 24.97%; Δ -0.51pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 219.8% (prev 243.8%; Δ -23.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -9.04 (EBITDA TTM -12.8m / Interest Expense TTM 3.74m) >= 6 (WARN >= 3) |
Altman Z'' 3.48
| (A) 0.21 = (Total Current Assets 286.9m - Total Current Liabilities 148.1m) / Total Assets 672.8m |
| (B) 0.49 = Retained Earnings (Balance) 326.8m / Total Assets 672.8m |
| (C) -0.05 = EBIT TTM -33.8m / Avg Total Assets 698.2m |
| (D) 0.83 = Book Value of Equity 305.2m / Total Liabilities 367.6m |
| Total Rating: 3.48 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 15.45
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -23.49% = -5.0 |
| 3. FCF Margin -3.56% = -1.34 |
| 4. Debt/Equity 0.36 = 2.44 |
| 5. Debt/Ebitda -6.91 = -2.50 |
| 6. ROIC - WACC (= -13.36)% = -12.50 |
| 7. RoE -10.83% = -1.81 |
| 8. Rev. Trend -91.14% = -6.84 |
| 9. EPS Trend -60.23% = -3.01 |
What is the price of TBI shares?
Over the past week, the price has changed by +3.59%, over one month by -17.34%, over three months by -18.98% and over the past year by -39.23%.
Is TrueBlue a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TBI is around 3.04 USD . This means that TBI is currently overvalued and has a potential downside of -38.09%.
Is TBI a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TBI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.7 | 76.6% |
| Analysts Target Price | 8.7 | 76.6% |
| ValueRay Target Price | 3.3 | -32.2% |
TBI Fundamental Data Overview November 01, 2025
P/E Forward = 56.1798
P/S = 0.0943
P/B = 0.5506
P/EG = 4.0048
Beta = 1.541
Revenue TTM = 1.53b USD
EBIT TTM = -33.8m USD
EBITDA TTM = -12.8m USD
Long Term Debt = 53.8m USD (from longTermDebt, last quarter)
Short Term Debt = 11.0m USD (from shortTermDebt, last quarter)
Debt = 110.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 88.2m USD (from netDebt column, last quarter)
Enterprise Value = 232.9m USD (144.7m + Debt 110.1m - CCE 21.9m)
Interest Coverage Ratio = -9.04 (Ebit TTM -33.8m / Interest Expense TTM 3.74m)
FCF Yield = -23.49% (FCF TTM -54.7m / Enterprise Value 232.9m)
FCF Margin = -3.56% (FCF TTM -54.7m / Revenue TTM 1.53b)
Net Margin = -2.21% (Net Income TTM -33.8m / Revenue TTM 1.53b)
Gross Margin = 24.47% ((Revenue TTM 1.53b - Cost of Revenue TTM 1.16b) / Revenue TTM)
Gross Margin QoQ = 23.61% (prev 23.32%)
Tobins Q-Ratio = 0.35 (Enterprise Value 232.9m / Total Assets 672.8m)
Interest Expense / Debt = 2.64% (Interest Expense 2.90m / Debt 110.1m)
Taxrate = -321.1% (out of range, set to none) (122.0k / -38.0k)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.94 (Total Current Assets 286.9m / Total Current Liabilities 148.1m)
Debt / Equity = 0.36 (Debt 110.1m / totalStockholderEquity, last quarter 305.2m)
Debt / EBITDA = -6.91 (negative EBITDA) (Net Debt 88.2m / EBITDA -12.8m)
Debt / FCF = -1.61 (negative FCF - burning cash) (Net Debt 88.2m / FCF TTM -54.7m)
Total Stockholder Equity = 312.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.03% (Net Income -33.8m / Total Assets 672.8m)
RoE = -10.83% (Net Income TTM -33.8m / Total Stockholder Equity 312.5m)
RoCE = -9.22% (EBIT -33.8m / Capital Employed (Equity 312.5m + L.T.Debt 53.8m))
RoIC = -6.72% (negative operating profit) (EBIT -33.8m / (Assets 672.8m - Curr.Liab 148.1m - Cash 21.9m))
WACC = 6.64% (E(144.7m)/V(254.8m) * Re(11.69%) + (debt cost/tax rate unavailable))
Discount Rate = 11.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.99%
Fair Price DCF = unknown (Cash Flow -54.7m)
EPS Correlation: -60.23 | EPS CAGR: -22.98% | SUE: -0.08 | # QB: 0
Revenue Correlation: -91.14 | Revenue CAGR: -12.70% | SUE: -0.30 | # QB: 0
Additional Sources for TBI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle